Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 102 articles: HTML format

Single Articles

December 2024
1. SPERLING LS
   The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?
   J Am Coll Cardiol. 2024;84:2260-2263.
   PubMed    
   
   
   
2. GYLDENKERNE C, Kahlert J, Thrane PG, Olesen KKW, et al
   2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study.
   J Am Coll Cardiol. 2024;84:2251-2259.
   PubMed     Abstract available
   
   
   November 2024
3. SANTOS-PARDO I, Andersson Franko M, Nystrom T
   Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
   J Am Coll Cardiol. 2024;84:e321.
   PubMed    
   
   
   
4. LIU C, Li X, Cong H
   Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
   J Am Coll Cardiol. 2024;84:e319-e320.
   PubMed    
   
   
   
5. WARRAICH HJ, Patrick-Lake B, Saha A, Rashid L, et al
   Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration.
   J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028.
   PubMed    
   
   
   
6. PATEL KV, Chunawala Z, Verma S, Segar MW, et al
   Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study.
   J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10417.
   PubMed     Abstract available
   
   
   September 2024
7. MENTZ RJ, Kittipibul V
   Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle.
   J Am Coll Cardiol. 2024;84:1089-1091.
   PubMed    
   
   
   
8. BHATT AS, Bhatt DL, Steg PG, Szarek M, et al
   Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
   J Am Coll Cardiol. 2024;84:1078-1088.
   PubMed     Abstract available
   
   
   
9. EVERETT BM, Wexler DJ
   Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease.
   J Am Coll Cardiol. 2024;84:918-920.
   PubMed    
   
   
   
10. KHERA R, Aminorroaya A, Dhingra LS, Thangaraj PM, et al
    Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    J Am Coll Cardiol. 2024;84:904-917.
    PubMed     Abstract available
    
    
    August 2024
11. MANUBOLU VS, Lakshmanan S, Kinninger A, Ahmad K, et al
    Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
    J Am Coll Cardiol. 2024;84:865-867.
    PubMed    
    
    
    
12. NEUEN BL, Ostrominski JW, Claggett B, Beldhuis IE, et al
    Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08155.
    PubMed    
    
    
    
13. PRATLEY RE, Tuttle KR, Rossing P, Rasmussen S, et al
    Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
    J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116.
    PubMed     Abstract available
    
    
    
14. NEUEN BL, Solomon SD
    Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:709-711.
    PubMed    
    
    
    
15. EDMONSTON D, Mulder H, Lydon E, Chiswell K, et al
    Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:696-708.
    PubMed     Abstract available
    
    
    
16. SHIN JI, Xu Y, Chang AR, Carrero JJ, et al
    Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    J Am Coll Cardiol. 2024;84:683-693.
    PubMed     Abstract available
    
    
    
17. OSTROMINSKI JW, Jemma Cho SM, Vaduganathan M, Honigberg MC, et al
    Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747.
    PubMed    
    
    
    
18. INZUCCHI SE, Arai AE
    Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    J Am Coll Cardiol. 2024;84:558-560.
    PubMed    
    
    
    
19. CHOWDHARY A, Thirunavukarasu S, Joseph T, Jex N, et al
    Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:540-557.
    PubMed     Abstract available
    
    
    July 2024
20. MARINHO LL, Everett BM, Aday AW, Visseren FLJ, et al
    Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.
    J Am Coll Cardiol. 2024;84:408-410.
    PubMed    
    
    
    
21. BABER U
    Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?
    J Am Coll Cardiol. 2024;84:273-275.
    PubMed    
    
    
    
22. GUGLIN M, Hillerson D
    Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities.
    J Am Coll Cardiol. 2024;84:244-246.
    PubMed    
    
    
    
23. LOPEZ J, Liu Y, Butler J, Del Prato S, et al
    Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.
    J Am Coll Cardiol. 2024;84:233-243.
    PubMed     Abstract available
    
    
    June 2024
24. VERMA S, Butler J, Borlaug BA, Davies M, et al
    Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
    J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445.
    PubMed     Abstract available
    
    
    
25. PINNEY SP, Costanzo MR
    As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
    J Am Coll Cardiol. 2024;83:2423-2425.
    PubMed    
    
    
    
26. LALA A, Mentz RJ, Santos-Gallego CG
    The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
    J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407.
    PubMed    
    
    
    May 2024
27. SANTOS-PARDO I, Andersson Franko M, Lagerqvist B, Ritsinger V, et al
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06933.
    PubMed     Abstract available
    
    
    April 2024
28. BONACA MP, Bhatt DL, Simon T, Fox KM, et al
    Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
    J Am Coll Cardiol. 2024;83:1627-1636.
    PubMed     Abstract available
    
    
    
29. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    PubMed     Abstract available
    
    
    
30. WONG ND, Fan W, Hu X, Ballantyne C, et al
    Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    J Am Coll Cardiol. 2024;83:1511-1525.
    PubMed     Abstract available
    
    
    
31. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    PubMed    
    
    
    
32. PACKER M
    SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
    J Am Coll Cardiol. 2024;83:1399-1402.
    PubMed    
    
    
    
33. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    PubMed     Abstract available
    
    
    
34. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    PubMed     Abstract available
    
    
    
35. COSTANZO MR, Januzzi JL
    Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    J Am Coll Cardiol. 2024;83:1307-1309.
    PubMed    
    
    
    
36. JANUZZI JL JR, Butler J, Del Prato S, Ezekowitz JA, et al
    Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613.
    PubMed     Abstract available
    
    
    March 2024
37. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e89.
    PubMed    
    
    
    
38. OHSHIRO Y
    Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e87.
    PubMed    
    
    
    
39. HANSEN MK, Olesen KKW, Gyldenkerne C, Thrane PG, et al
    Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    J Am Coll Cardiol. 2024;83:956-958.
    PubMed    
    
    
    February 2024
40. KRISHNARAJ A, Bakbak E, Teoh H, Pan Y, et al
    Vascular Regenerative Cell Deficiencies in South Asian Adults.
    J Am Coll Cardiol. 2024;83:755-769.
    PubMed     Abstract available
    
    
    
41. SCHIAVON CA, Cavalcanti AB, Oliveira JD, Machado RHV, et al
    Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years.
    J Am Coll Cardiol. 2024;83:637-648.
    PubMed     Abstract available
    
    
    January 2024
42. PACKER M
    Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:371-381.
    PubMed     Abstract available
    
    
    November 2023
43. VADUGANATHAN M, Ostrominski JW
    Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide.
    J Am Coll Cardiol. 2023;82:2097-2100.
    PubMed    
    
    
    
44. COCA SG
    SGLT2i and Deterioration of Kidney Function in Heart Failure: Another Demonstration for Tolerance of "Hypercreatininemia".
    J Am Coll Cardiol. 2023;82:1864-1867.
    PubMed    
    
    
    
45. FONAROW GC, Mohebi R
    Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level.
    J Am Coll Cardiol. 2023;82:1852-1853.
    PubMed    
    
    
    
46. AGGARWAL R, Bhatt DL, Szarek M, Cannon CP, et al
    Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
    J Am Coll Cardiol. 2023;82:1842-1851.
    PubMed     Abstract available
    
    
    October 2023
47. BLAHA MJ, Khorsandi M
    Type 2 Diabetes Mellitus: Now in the Cardiologist's Wheelhouse.
    J Am Coll Cardiol. 2023;82:1595-1597.
    PubMed    
    
    
    
48. GYLDENKERNE C, Mortensen MB, Kahlert J, Thrane PG, et al
    10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;82:1583-1594.
    PubMed     Abstract available
    
    
    
49. OHSHIRO Y
    Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories.
    J Am Coll Cardiol. 2023;82:e133.
    PubMed    
    
    
    August 2023
50. CHATUR S, Vaduganathan M, Claggett BL, Mc Causland FR, et al
    Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to <25ml/min/1.73m(2).
    J Am Coll Cardiol. 2023 Aug 23:S0735-1097(23)06532.
    PubMed     Abstract available
    
    
    
51. ARODA VR, Billings LK
    GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
    J Am Coll Cardiol. 2023;82:526-528.
    PubMed    
    
    
    
52. NEVES JS, Borges-Canha M, Vasques-Novoa F, Green JB, et al
    GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2023;82:517-525.
    PubMed     Abstract available
    
    
    
53. KONDO T, Wang X, Yang M, Jhund PS, et al
    Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
    J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05964.
    PubMed     Abstract available
    
    
    July 2023
54. MORALES J, Handelsman Y
    Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:161-170.
    PubMed     Abstract available
    
    
    June 2023
55. BRUMMEL K, Eagle K
    An Atherothrombotic Risk Score for Patients With Diabetes: Useful Tool or More of the Same?
    J Am Coll Cardiol. 2023;81:2403-2405.
    PubMed    
    
    
    
56. BERG DD, Moura FA, Bellavia A, Scirica BM, et al
    Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;81:2391-2402.
    PubMed     Abstract available
    
    
    
57. WIVIOTT SD, Berg DD
    SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency.
    J Am Coll Cardiol. 2023;81:2388-2390.
    PubMed    
    
    
    
58. USMAN MS, Siddiqi TJ, Anker SD, Bakris GL, et al
    Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
    J Am Coll Cardiol. 2023;81:2377-2387.
    PubMed     Abstract available
    
    
    May 2023
59. SUKUMAR S, Wasfy JH, Januzzi JL, Peppercorn J, et al
    Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;81:2043-2055.
    PubMed     Abstract available
    
    
    
60. KRISTENSEN SL, Jensen J, Schou M
    SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
    J Am Coll Cardiol. 2023;81:1915-1917.
    PubMed    
    
    
    
61. BUTLER J, Packer M, Siddiqi TJ, Bohm M, et al
    Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
    J Am Coll Cardiol. 2023;81:1902-1914.
    PubMed     Abstract available
    
    
    April 2023
62. VERMA S, Bhatt DL, Dhingra NK, Steg PG, et al
    Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
    J Am Coll Cardiol. 2023;81:1546-1549.
    PubMed    
    
    
    
63. KHAN H, Kunutsor SK
    Nonsteroidal Anti-Inflammatory Drugs and Type 2 Diabetes: A Recipe for Heart Failure?
    J Am Coll Cardiol. 2023;81:1471-1473.
    PubMed    
    
    
    
64. HOLT A, Strange JE, Nouhravesh N, Nielsen SK, et al
    Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;81:1459-1470.
    PubMed     Abstract available
    
    
    January 2023
65. TAGGART C, Monterrubio-Gomez K, Roos A, Boeddinghaus J, et al
    Improving Risk Stratification for Patients With Type 2 Myocardial Infarction.
    J Am Coll Cardiol. 2023;81:156-168.
    PubMed     Abstract available
    
    
    December 2022
66. AN P, Wan S, Luo Y, Luo J, et al
    Micronutrient Supplementation to Reduce Cardiovascular Risk.
    J Am Coll Cardiol. 2022;80:2269-2285.
    PubMed     Abstract available
    
    
    
67. HATHAWAY QA, Yanamala N, Siva NK, Adjeroh DA, et al
    Ultrasonic Texture Features for Assessing Cardiac Remodeling and Dysfunction.
    J Am Coll Cardiol. 2022;80:2187-2201.
    PubMed     Abstract available
    
    
    November 2022
68. AL-KINDI S, Motairek I, Janus S, Deo S, et al
    Time-Varying Cardiovascular Effects of Finerenone in Diabetic Kidney Disease: Insights From FIDELIO-DKD and FIGARO-DKD Trials.
    J Am Coll Cardiol. 2022;80:1855-1856.
    PubMed    
    
    
    
69. NASSIF ME, Januzzi JL Jr
    Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure: What Is the Message to DELIVER?
    J Am Coll Cardiol. 2022;80:1785-1787.
    PubMed    
    
    
    
70. VADUGANATHAN M, Claggett BL, Jhund P, de Boer RA, et al
    Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
    J Am Coll Cardiol. 2022;80:1775-1784.
    PubMed     Abstract available
    
    
    
71. ZANNAD F
    Heart Failure and Kidney Disease in Type 2 Diabetes: 2 Sides of the Same Coin.
    J Am Coll Cardiol. 2022;80:1732-1734.
    PubMed    
    
    
    
72. SARRAJU A, Bakris G, Cannon CP, Cherney D, et al
    Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    J Am Coll Cardiol. 2022;80:1721-1731.
    PubMed     Abstract available
    
    
    September 2022
73. KERN MJ, Seto AH
    Does Diabetes Affect Angiographically Derived (QFR) Translesional Physiology?: Looking at the FAVOR III Diabetic Subset.
    J Am Coll Cardiol. 2022;80:1265-1267.
    PubMed    
    
    
    
74. JIN Z, Xu B, Yang X, Jia R, et al
    Coronary Intervention Guided by Quantitative Flow Ratio vs Angiography in Patients With or Without Diabetes.
    J Am Coll Cardiol. 2022;80:1254-1264.
    PubMed     Abstract available
    
    
    
75. WANG N, Harris K, Hamet P, Harrap S, et al
    Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
    J Am Coll Cardiol. 2022;80:1147-1155.
    PubMed     Abstract available
    
    
    August 2022
76. AHMAD T, Desai NR, Velazquez EJ
    SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure.
    J Am Coll Cardiol. 2022 Aug 26. pii: S0735-1097(22)05770.
    PubMed    
    
    
    
77. MOHEBI R, Chen C, Ibrahim NE, McCarthy CP, et al
    Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates.
    J Am Coll Cardiol. 2022;80:565-578.
    PubMed     Abstract available
    
    
    July 2022
78. KOTTKE TE, Gupta AK, Thomas RJ
    Failing Cardiovascular Health: A Population Code Blue.
    J Am Coll Cardiol. 2022;80:152-154.
    PubMed    
    
    
    June 2022
79. FARIDI KF, Dayoub EJ, Ross JS, Dhruva SS, et al
    Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.
    J Am Coll Cardiol. 2022;79:2516-2525.
    PubMed     Abstract available
    
    
    
80. VERMA S, Pandey A, Bhatt DL
    Forecasting Heart Failure Risk in Diabetes.
    J Am Coll Cardiol. 2022;79:2294-2297.
    PubMed    
    
    
    
81. ECHOUFFO-TCHEUGUI JB, Ndumele CE, Zhang S, Florido R, et al
    Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study.
    J Am Coll Cardiol. 2022;79:2285-2293.
    PubMed     Abstract available
    
    
    
82. HAUGE MG, Damm P, Kofoed KF, Ersboll AS, et al
    Early Coronary Atherosclerosis in Women With Previous Preeclampsia.
    J Am Coll Cardiol. 2022;79:2310-2321.
    PubMed     Abstract available
    
    
    May 2022
83. UDELL JA, Jones WS, Petrie MC, Harrington J, et al
    Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2022;79:2058-2068.
    PubMed     Abstract available
    
    
    
84. STUART JJ, Tanz LJ, Rimm EB, Spiegelman D, et al
    Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With Hypertensive Disorders of Pregnancy.
    J Am Coll Cardiol. 2022;79:1901-1913.
    PubMed     Abstract available
    
    
    
85. KELSEY MD, Nelson AJ, Green JB, Granger CB, et al
    Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.
    J Am Coll Cardiol. 2022;79:1849-1857.
    PubMed     Abstract available
    
    
    
86. BEHAN SA, Mulder H, Rockhold FW, Gutierrez JA, et al
    Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease.
    J Am Coll Cardiol. 2022;79:1781-1783.
    PubMed    
    
    
    April 2022
87. REGENSTEINER JG, Reusch JEB
    Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes: JACC Focus Seminar 4/7.
    J Am Coll Cardiol. 2022;79:1492-1505.
    PubMed     Abstract available
    
    
    
88. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.
    J Am Coll Cardiol. 2022;79:1458-1473.
    PubMed     Abstract available
    
    
    March 2022
89. GHAZI L, Yamamoto Y, Riello RJ, Coronel-Moreno C, et al
    Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
    J Am Coll Cardiol. 2022 Mar 19. pii: S0735-1097(22)04489.
    PubMed     Abstract available
    
    
    February 2022
90. VADUGANATHAN M, Sattar N, Xu J, Butler J, et al
    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    J Am Coll Cardiol. 2022;79:432-444.
    PubMed     Abstract available
    
    
    January 2022
91. VASAN RS, Enserro DM, Beiser AS, Xanthakis V, et al
    Lifetime Risk of Heart Failure Among Participants in the Framingham Study.
    J Am Coll Cardiol. 2022;79:250-263.
    PubMed     Abstract available
    
    
    
92. VOLGMAN AS, Nair G, Lyubarova R, Merchant FM, et al
    Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2022;79:166-179.
    PubMed     Abstract available
    
    
    December 2021
93. JOSEPH JJ, Ortiz R, Acharya T, Golden SH, et al
    Cardiovascular Impact of Race and Ethnicity in Patients With Diabetes and Obesity: JACC Focus Seminar 2/9.
    J Am Coll Cardiol. 2021;78:2471-2482.
    PubMed     Abstract available
    
    
    
94. LAWTON JS, Tamis-Holland JE, Bangalore S, Bates ER, et al
    2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    J Am Coll Cardiol. 2021 Dec 7. pii: S0735-1097(21)06157.
    PubMed     Abstract available
    
    
    November 2021
95. RAO VN, Murray E, Butler J, Cooper LB, et al
    In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.
    J Am Coll Cardiol. 2021;78:2004-2012.
    PubMed     Abstract available
    
    
    October 2021
96. ARODA VR, Taub PR, Stanton AM
    Diabetes With Cardiomyopathy: At the Juncture of Knowledge and Prevention.
    J Am Coll Cardiol. 2021;78:1599-1602.
    PubMed    
    
    
    
97. SEGAR MW, Khan MS, Patel KV, Butler J, et al
    Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.
    J Am Coll Cardiol. 2021;78:1587-1598.
    PubMed     Abstract available
    
    
    
98. ROSSELLO X, Ibanez B, Fuster V
    Reply: What Is Behind the HbA1c Value?
    J Am Coll Cardiol. 2021;78:e119.
    PubMed    
    
    
    
99. TANAKA A, Node K
    What Is Behind the HbA1c Value?
    J Am Coll Cardiol. 2021;78:e117.
    PubMed    
    
    
    June 2021
100. GRAHAM IM, Di Angelantonio E, Visseren F, De Bacquer D, et al
     Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8.
     J Am Coll Cardiol. 2021;77:3046-3057.
     PubMed     Abstract available
     
     
     May 2021
101. HONIGBERG MC, Zekavat SM, Pirruccello JP, Natarajan P, et al
     Cardiovascular and Kidney Outcomes across the Glycemic Spectrum: Insights from the UK Biobank.
     J Am Coll Cardiol. 2021 May 11. pii: S0735-1097(21)05045.
     PubMed     Abstract available
     
     
     March 2021
102. PACKER M, Anker SD, Butler J, Filippatos G, et al
     Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
     J Am Coll Cardiol. 2021;77:1381-1392.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.